Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Ironwood Pharmaceuticals (IRWD) over the last 12 years, with Q3 2025 value amounting to $385.0 million.

  • Ironwood Pharmaceuticals' Non-Current Debt fell 375.0% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $385.0 million, marking a year-over-year decrease of 375.0%. This contributed to the annual value of $385.0 million for FY2024, which is 2833.33% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Non-Current Debt is $385.0 million, which was down 375.0% from $385.0 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Debt peaked at $425.0 million during Q2 2024, and registered a low of $275.0 million during Q1 2024.
  • For the 3-year period, Ironwood Pharmaceuticals' Non-Current Debt averaged around $366.5 million, with its median value being $385.0 million (2024).
  • Over the last 5 years, Ironwood Pharmaceuticals' Non-Current Debt had its largest YoY gain of 4000.0% in 2025, and its largest YoY loss of 941.18% in 2025.
  • Quarter analysis of 3 years shows Ironwood Pharmaceuticals' Non-Current Debt stood at $300.0 million in 2023, then rose by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025.
  • Its last three reported values are $385.0 million in Q3 2025, $385.0 million for Q2 2025, and $385.0 million during Q1 2025.